Skip to main content
PlainMeds

What the label lists and what reports show

Diflorasone side effects

Diflorasone's FDA label lists its adverse reactions in its own words. FAERS holds 188 reports naming it through July 30, 2026; the reaction reported most often, leaving out the conditions it is used for, product-use terms and outcomes, is psoriasis (16 reports).

  • Generic listed

Check it at the source: the diflorasone FDA label on DailyMed (effective May 2, 2023, Rising Pharma Holdings, Inc.); the FDA FAERS public dashboard.

What does the label list?

From the label: adverse reactions

The following local adverse reactions have been reported with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in approximate decreasing order of occurrence: 1. Burning 2. Itching 3. Irritation 4. Dryness 5. Folliculitis 6. Hypertrichosis 7. Acneiform eruptions 8. Hypopigmentation 9. Perioral dermatitis 10. Allergic contact dermatitis 11. Maceration of the skin 12. Secondary infection 13. Skin atrophy 14. Striae 15. Miliaria To report SUSPECTED ADVERSE REACTIONS, contact Rising Pharmaceuticals, Inc. at 1-844-874-7464 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Source: FDA drug label, Rising Pharma Holdings, Inc., effective May 2, 2023 (SPL set 23eb27a4-157f-4eb5-a390-37586710808f), via openFDA; the full label on DailyMed

What do FAERS reports show?

188 reports list diflorasone among the medicines taken, each a report of something that happened, not proof the medicine caused it; 11 are coded as a death and 73 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Of the 24 reactions below, none is named by the same term (in US spelling) in the label's adverse reactions, warnings or patient leaflet; a reaction the label does not name may still be there under another word, and a report does not show that the medicine caused it.

The 25 most reported reactions

Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026; reactions as MedDRA preferred terms

What next?

Diflorasone: the full record
label, generics, price, shortages, recalls
Side effects hub
the most reported medicines and reactions